iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
iBio to Participate in Upcoming Investor Conferences
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio Announces $26 Million Private Placement
iBio to Participate in the 8th Annual Evercore Healthcare Conference
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.